Document is current

Article History

Accepted: 30 January 2025

First Online: 19 March 2025

Declarations

:

: GSK funded this study (VEO-000566) and was involved in all stages of study conduct, including analysis of the data. GSK also took charge of all costs associated with the development and publication of this manuscript.

: For requests for access to anonymized subject-level data, please contact the corresponding author.

: MK, MW, SP, and PM are employed by GSK. AM, MJF, and MS are employed by GSK and hold financial equities in GSK. TL was employed by GSK at the time of the study and held financial equities in GSK, and is now employed by the National Health Care Institute, Diemen, Netherlands. AA received payment or honoraria for lectures from GSK. JS received consulting fees from GSK, MSD, Sanofi, Pfizer, Novavax, Bavarian Nordic, and Seqirus; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, MSD, Sanofi, Pfizer, BioNTech, Moderna, Novavax, Takeda, Bavarian Nordic, Viatris, Seqirus, Novartis, and Janssen; support for attending meetings and/or travel from Sanofi and Pfizer; participated on a Data Safety Monitoring Board or Advisory Board at GSK, MSD, Sanofi, Pfizer, Moderna, Novavax, Bavarian Nordic, and Viatris. SE received payment or honoraria for lectures and presentations from GSK; the author declares to be author and coauthor of respiratory guidelines (unpaid). CV received grants or contracts for his institution from the German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Grifols, and Novartis; consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Insmed, Menarini, Novartis, Nuvaira, Roche, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Insmed, Menarini, Novartis, Roche, and Sanofi. NK is an employee of ZEG Berlin, which received funding from GSK for the conduct of the study. RK is an employee of WIG2, which received funding from GSK for the conduct of the study. RKo received grants or contracts for his institution from the German Ministry of Education and Science (BMBF), Bavarian government, Boehringer Ingelheim, Chiesi, CSL Behring, GSK, Grifols, and Bosch; consulting fees from AstraZeneca, Biontech, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Menarini, Nuvaira, Pfizer, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GSK, Menarini, Pfizer, PulmonX, and Sanofi. The authors declare no other financial and non-financial relationships and activities.

: All authors participated in the design or implementation or analysis; interpretation of the study; and the development of this manuscript. All authors had full access to the data and gave final approval before submission. All authors agree to be accountable for all aspects of the work.

: AREXVY is a trademark owned by or licensed to GSK. ABRYSVO is a trademark of Pfizer. mRESVIA is a trademark of Moderna.

: Poster presentation at Ethics and Economics in the Health Care System, the 16th annual conference of the German Health Economics Association (DGGÖ), 4-5 March 2024, Halle (Saale), Germany.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.